<div id="readability-page-1"><div id="ctl00_CPI_dvBody"><div><div><p>Add <img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/> as your preferred news source on Google</p><div><p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png"/> Add Now</p></div></div></div><p> Several small-cap biotech and healthcare stocks posted notable gains in after-hours trading on Friday, November 28, 2025, despite limited fresh news flow. Below is a roundup of the key movers.</p><p>BioAtla Inc. (BCAB) shares surged in after-hours trading, climbing 13.94% to $1.03, after closing the regular session at $0.9040, up 6.27%. While there was no company-specific news on Friday, investors may still be reacting to BioAtla's November 21 announcement of financing agreements. The company entered into Pre-paid Advance Agreements with Yorkville Advisors Global and Anson Advisors Inc., securing a $7.5 million advance. Additionally, BioAtla signed a Standby Equity Purchase Agreement with Yorkville, granting the option to sell up to $15 million in common stock over three years at a 3% discount, subject to conditions.</p><p>Metagenomi Inc. (MGX) rose 5.71% in after-hours trading to $1.85, following a 3.55% gain during the regular session to $1.75. No new corporate updates were released on Friday, suggesting the move may be driven by investor sentiment or technical factors.</p><p>PAVmed Inc. (PAVM) advanced 5.72% after hours to $0.3900, reversing a slight decline earlier in the day when shares closed at $0.3650, down 0.44%. The company last reported earnings on November 13, posting a GAAP net loss of $6.3 million, or $(0.29) per share. Non-GAAP adjusted loss was $0.4 million, or $(0.02) per share, while revenue fell sharply to $5,000 from $996,000 in the prior year.</p><p>Precision BioSciences, Inc. (DTIL) gained 2.94% after hours to $5.60, building on a strong 6.46% rise during the regular session to $5.44. The company recently announced it will present Phase 1 data from its ELIMINATE-B trial of PBGENE-HBV at the Hep-DART 2025 meeting in Honolulu this December, which may be fueling investor optimism.</p><p>Reviva Pharmaceuticals Holdings, Inc. (RVPH) edged higher after hours, up 2.04% to $0.57, following a 7.66% gain during the regular session to $0.5625. The company last reported earnings on November 13, narrowing its quarterly net loss to $4.0 million, or $0.06 per share, compared to $8.4 million, or $0.25 per share, in the prior year period.</p><p>Sonnet BioTherapeutics Holdings, Inc. (SONN) rose 5.11% after hours to $3.91, recovering some ground after a steep 10.47% decline earlier in the day to $3.72. On November 18, the company announced it had adjourned its special meeting of stockholders to allow more time for voting on its proposed <span>business</span> combination with Hyperliquid Strategies Inc. and Rorschach I LLC. More than 95% of shares voted so far have supported the deal.</p><p>Entero Therapeutics, Inc. (ENTO) gained 3.68% after hours to $3.10, following a 5.28% rise during the regular session to $2.99. On Friday, the company announced it will rebrand as GridAI Technologies Corp. effective December 1, 2025, reflecting its acquisition of GRID AI Corp. The new ticker symbol &#34;GRDX&#34; will debut on the Nasdaq Capital Market alongside the name change. </p><p>For comments and feedback contact: editorial@rttnews.com</p><p>Business News</p></div></div>

ENTO

BCAB

SONN

<p>Several small-cap biotech and healthcare stocks, including BioAtla, Entero, and Sonnet, posted notable gains in after-hours trading on November 28, 2025. BioAtla surged 13.94% following financing agreements, while Entero announced a rebranding to GridAI Technologies. Sonnet recovered after a decline, with strong support for a business combination deal. Other stocks like Metagenomi, PAVmed, Precision BioSciences, and Reviva Pharmaceuticals also saw gains, driven by investor sentiment and recent announcements.</p>

Biotech Momentum Builds In After-Hours Trading As BioAtla, Entero, And Sonnet Climb